Vardenafil hydrochloride
(Synonyms: 盐酸伐地那非) 目录号 : GC37888An inhibitor of PDE5 and PDE6
Cas No.:224785-91-5
Sample solution is provided at 25 µL, 10mM.
Vardenafil is a potent inhibitor of phosphodiesterase 5 (PDE5; IC50s = 0.2-1.2 nM) and PDE6 (IC50 = 2 nM).1,2,3 It is selective for PDE5 and PDE6 over PDE1 and PDE11 (IC50s = 230 and 130 nM, respectively). Vardenafil (4 mg/kg per day for three weeks) improves erectile function in a rat model of acute arteriogenic erectile dysfunction by increasing intracavernous pressure and mean arterial pressure, and this effect persists for at least two weeks following the end of treatment.4 Chronic vardenafil administration at a dose of 2 mg/kg for five weeks in subordinate mice reduces the latency to mount and increases the frequency of mounting behavior.5 Formulations containing vardenafil have been used in the treatment of erectile dysfunction.
1.Card, G.L., England, B.P., Suzuki, Y., et al.Structural basis for the activity of drugs that inhibit phosphodiesterasesStructure12(12)2233-2247(2004) 2.Boyle, C.D., Xu, R., Asberom, T., et al.Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male EDBioorg. Med. Chem. Lett.15(9)2365-2369(2005) 3.Smith, W.B., II, McCaslin, I.R., Gokce, A., et al.PDE5 inhibitors: Considerations for preference and long-term adherenceInt. J. Clin. Pract.67(8)768-780(2013) 4.Hotta, Y., Ohno, R., Kataoka, T., et al.Effects of chronic vardenafil treatment persist after end of treatment in rats with acute arteriogenic erectile dysfunctionJ. Sex Med.9(7)1782-1788(2012) 5.Dadomo, H., Parmigiani, S., Nicolini, Y., et al.Repeated and chronic administration of Vardenafil or Sildenafil differentially affects emotional and socio-sexual behavior in miceBehav. Brain Res.253103-112(2013)
Cas No. | 224785-91-5 | SDF | |
别名 | 盐酸伐地那非 | ||
Canonical SMILES | CCCC1=NC(C)=C2N1N=C(C(C=C(S(=O)(N3CCN(CC)CC3)=O)C=C4)=C4OCC)NC2=O.Cl | ||
分子式 | C23H33ClN6O4S | 分子量 | 525.06 |
溶解度 | DMSO: 100 mg/mL (190.45 mM); Water: ≥ 100 mg/mL (190.45 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9045 mL | 9.5227 mL | 19.0454 mL |
5 mM | 0.3809 mL | 1.9045 mL | 3.8091 mL |
10 mM | 0.1905 mL | 0.9523 mL | 1.9045 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet